Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

ValiRx (LSE:VAL) in Focus Today: ValiRx remains in focus around its oncology and life-science intellectual property portfolio, including progress around Cytolytix and its strategic investment position.

On 9 November 2026, ValiRx (LSE:VAL) is in focus as investors assess the latest company-specific catalyst and what it could mean for the next stage of the business. The immediate reason for attention is valirx remains in focus around its oncology and life-science intellectual …

Ankur Sharma | 09 November 2026

Thalia Therapeutics (LSE:THAT) in Focus Today: Thalia Therapeutics remains in focus around its therapeutic development programme and the milestones needed to advance its biotechnology platform.

On 9 November 2026, Thalia Therapeutics (LSE:THAT) is in focus as investors assess the latest company-specific catalyst and what it could mean for the next stage of the business. The immediate reason for attention is thalia therapeutics remains in focus around its therapeutic development …

Ankur Sharma | 09 November 2026

FTSE AIM All-Share: Diagnostics Momentum Puts Surgical Innovations Group plc (LSE:SUN)

5 November director dealings and the September half-year report have kept attention on execution in minimally invasive surgery.

Ankur Sharma | 09 November 2026

Shield Therapeutics (LSE:STX) in Focus Today: Q3 2026 showed continued commercial sales growth, while the company took full US commercial control of ACCRUFeR, changing its economics and cost structure.

On 9 November 2026, Shield Therapeutics (LSE:STX) is in focus as investors assess the latest company-specific catalyst and what it could mean for the next stage of the business. The immediate reason for attention is q3 2026 showed continued commercial sales growth, while the …

Ankur Sharma | 09 November 2026

Sareum (LSE:SAR) in Focus Today: Sareum remains in focus around its oncology drug-development programme and the clinical milestones needed to establish commercial value.

On 9 November 2026, Sareum (LSE:SAR) is in focus as investors assess the latest company-specific catalyst and what it could mean for the next stage of the business. The immediate reason for attention is sareum remains in focus around its oncology drug-development programme and …

Ankur Sharma | 09 November 2026

RUA Life Sciences (LSE:RUA) in Focus Today: RUA Life Sciences remains in focus around its biomaterials technology, medical-device opportunities and the conversion of development work into commercial revenues.

On 9 November 2026, RUA Life Sciences (LSE:RUA) is in focus as investors assess the latest company-specific catalyst and what it could mean for the next stage of the business. The immediate reason for attention is rua life sciences remains in focus around its …

Ankur Sharma | 09 November 2026

Renalytix (LSE:RENX) in Focus Today: Renalytix remains on the radar as investors monitor commercialisation of its kidney-disease testing technology and the company's financial runway.

On 9 November 2026, Renalytix (LSE:RENX) is in focus as investors assess the latest company-specific catalyst and what it could mean for the next stage of the business. The immediate reason for attention is renalytix remains on the radar as investors monitor commercialisation of …

Ankur Sharma | 09 November 2026

AIM Thalia Therapeutics (LSE:THAT): A clinical trial agreement for miristen, its that-001 rna therapeutic programme puts shares in focus today

• Thalia has transformed into a clinical-stage RNA therapeutics company following theAcquisitionof Sanmirna Therapeutics. Its Phase 1 study of THAT-001, or miRisten, in relapsed or refractory acute myeloid leukaemia is progressing, with top-line data targeted for the first half of 2027.

Ankur Sharma | 09 November 2026

Main Market RTW Venture Fund (LSE:RTWG): An expansion of its capital allocation plan across innovative life-sciences investments puts shares in focus today

• RTW Venture Fund provides listed exposure to a portfolio of biotechnology and life-sciences companies, with capital allocation linked to clinical and commercial milestones. An expansion of the capital allocation plan can affect portfolio construction,Liquidityand the pace at which new opportunities are funded.

Ankur Sharma | 09 November 2026

AIM Oxford Biodynamics (LSE:OBD): An operational update on its episwitch technology, clinical programmes and commercial development puts shares in focus today

• Oxford Biodynamics develops epigenetic biomarkers using its EpiSwitch platform, with applications across oncology, diagnostics and drug development. ItsInvestmentcase is linked to scientific validation, partnerships, commercial adoption and the conversion of research programmes intoRecurring Revenueopportunities.

Ankur Sharma | 09 November 2026
Support

Hi! How can we help you today?

Loading…